Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients

Yu Zuo, Mark Warnock, Alyssa Harbaugh, Srilakshmi Yalavarthi, Kelsey Gockman, Melanie Zuo, Jacqueline A. Madison, View ORCID ProfileJason S. Knight, Yogendra Kanthi, Daniel A. Lawrence
doi: https://doi.org/10.1101/2020.08.29.20184358
Yu Zuo
1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Warnock
2Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alyssa Harbaugh
1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Srilakshmi Yalavarthi
1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelsey Gockman
1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie Zuo
3Division of Geriatric and Palliative Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline A. Madison
1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason S. Knight
1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jason S. Knight
Yogendra Kanthi
4Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
5Laboratory of Vascular Thrombosis and Inflammation, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel A. Lawrence
2Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dlawrenc@umich.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Patients with coronavirus disease-19 (COVID-19) are at high risk for thrombotic arterial and venous occlusions. However, bleeding complications have also been observed in some patients. Understanding the balance between coagulation and fibrinolysis will help inform optimal approaches to thrombosis prophylaxis and potential utility of fibrinolytic-targeted therapies. 118 hospitalized COVID-19 patients and 30 healthy controls were included in the study. We measured plasma antigen levels of tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) and performed spontaneous clot-lysis assays. We found markedly elevated tPA and PAI-1 levels in patients hospitalized with COVID-19. Both factors demonstrated strong correlations with neutrophil counts and markers of neutrophil activation. High levels of tPA and PAI-1 were associated with worse respiratory status. High levels of tPA, in particular, were strongly correlated with mortality and a significant enhancement in spontaneous ex vivo clot-lysis. While both tPA and PAI-1 are elevated among COVID-19 patients, extremely high levels of tPA enhance spontaneous fibrinolysis and are significantly associated with mortality in some patients. These data indicate that fibrinolytic homeostasis in COVID-19 is complex with a subset of patients expressing a balance of factors that may favor fibrinolysis. Further study of tPA as a biomarker is warranted.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The work was supported by a COVID-19 Cardiovascular Impact Research Ignitor Grant from the Michigan Medicine Frankel Cardiovascular Center, the A. Alfred Taubman Medical Research Institute, and the National Institutes of Health (HL055374 to DAL).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study complied with all relevant ethical regulations and was approved by the University of Michigan IRB (HUM00179409).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Disclosures: Daniel A. Lawrence is a member of the board and holds equity in MDI Therapeutics which is developing therapeutic inhibitors of PAI-1.

Data Availability

All data will be made available upon publication.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 05, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
Yu Zuo, Mark Warnock, Alyssa Harbaugh, Srilakshmi Yalavarthi, Kelsey Gockman, Melanie Zuo, Jacqueline A. Madison, Jason S. Knight, Yogendra Kanthi, Daniel A. Lawrence
medRxiv 2020.08.29.20184358; doi: https://doi.org/10.1101/2020.08.29.20184358
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
Yu Zuo, Mark Warnock, Alyssa Harbaugh, Srilakshmi Yalavarthi, Kelsey Gockman, Melanie Zuo, Jacqueline A. Madison, Jason S. Knight, Yogendra Kanthi, Daniel A. Lawrence
medRxiv 2020.08.29.20184358; doi: https://doi.org/10.1101/2020.08.29.20184358

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (166)
  • Anesthesia (49)
  • Cardiovascular Medicine (447)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (188)
  • Epidemiology (5195)
  • Forensic Medicine (3)
  • Gastroenterology (192)
  • Genetic and Genomic Medicine (746)
  • Geriatric Medicine (76)
  • Health Economics (210)
  • Health Informatics (689)
  • Health Policy (350)
  • Health Systems and Quality Improvement (221)
  • Hematology (98)
  • HIV/AIDS (161)
  • Infectious Diseases (except HIV/AIDS) (5787)
  • Intensive Care and Critical Care Medicine (353)
  • Medical Education (101)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (754)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (140)
  • Occupational and Environmental Health (230)
  • Oncology (473)
  • Ophthalmology (149)
  • Orthopedics (37)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (138)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (135)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (851)
  • Public and Global Health (1982)
  • Radiology and Imaging (340)
  • Rehabilitation Medicine and Physical Therapy (154)
  • Respiratory Medicine (282)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (74)
  • Surgery (107)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)